PCOS Long-Term: Managing Metabolic Risk and Protecting the Endometrium
PCOS is a lifelong condition whose manifestations evolve with age. The acne and irregular periods that dominate in the teenage years give way to fertility concerns in the twenties and thirties, and then to metabolic and endometrial cancer risk in the forties and beyond. Effective long-term management requires a proactive, multi-system approach rather than treating each symptom in isolation.
Protecting the Endometrium
The most important gynaecological priority for women with PCOS is ensuring that the endometrium sheds regularly. The target is at least 4 induced bleeds per year in women not using hormonal contraception. Options include:
- Combined oral contraceptive pill — regulates cycles, reduces androgens, and provides reliable endometrial protection; first-line in women not trying to conceive
- Cyclical progestogen — medroxyprogesterone acetate or norethisterone given for 12–14 days every 1–3 months to induce a withdrawal bleed; useful for women who cannot use oestrogen-containing contraception
- Levonorgestrel IUS — provides continuous endometrial protection; suitable for women with PCOS who also have heavy bleeding
Managing Insulin Resistance
Insulin resistance underlies a significant proportion of PCOS pathophysiology. Elevated insulin drives androgen production from the ovaries and promotes endometrial proliferation. Addressing insulin resistance:
- Weight loss of 5–10% of body weight in overweight women significantly improves ovulation and metabolic markers
- Regular aerobic exercise (150 min/week) improves insulin sensitivity independently of weight loss
- Metformin reduces insulin resistance and modestly improves ovulation; used particularly when lifestyle measures are insufficient or when fertility treatment is planned
When to Seek Oncological Assessment
Women with PCOS should be referred for oncological assessment if they experience any of the following: irregular or abnormal bleeding in the perimenopause; endometrial thickness above 10 mm on ultrasound in a premenopausal woman; endometrial hyperplasia found on biopsy (particularly atypical hyperplasia); or any postmenopausal bleeding. Atypical endometrial hyperplasia carries a 30% risk of concurrent endometrial cancer and requires surgical management.
Dr. Nishtha Tripathi Patel sees women with PCOS and gynaecological cancer concerns at her Ahmedabad clinics. Contact: +91 76988 00333.